Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology

Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug…

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Toronto, Ontario–(Newsfile Corp. – September 24, 2024) – Cardiol Therapeutics Inc. (NASDAQ:…